@article{de46ff3ff0d9462582241c59b7dc05e8,
title = "Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy",
abstract = "It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.",
author = "Naveen Pemmaraju and Hagop Kantarjian and Loretta Nastoupil and Megan Dupuis and Lisa Zhou and Sherry Pierce and Patel, {Keyur P.} and Lucia Masarova and Jorge Cortes and Srdan Verstovsek",
note = "Funding Information: This research is supported in part by MD Anderson Cancer Center Support Grant P30 CA016672. Funding Information: Conflict-of-interest disclosure: N.P. received consulting fees and honoraria from Celgene, Stemline, Incyte, Novartis, MustangBio, Roche Diagnostics, and LFB and research funding and clinical trials support from Stemline, Novartis, Abbvie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, Affymetrix, and the SagerStrong Foundation. H.K. received research funding and grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer, and Incyte and honoraria from AbbVie, Actinium (advisory board), Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda. L.N. received honoraria from Celgene, Genentech, Gilead, Janssen, Novartis, Spectrum, and TG Therapeutics. L.M. received research funding from Incyte. J.C. is a consultant for BMS, Novartis, Pfizer, Takeda, Astellas, Jazz, and Daiichi and received research support (for the institution) from BMS, Novartis, Pfizer, Takeda, Astellas, Jazz, Daiichi, Incyte, Immunogen, Merus, and Amphivena. S.V. received research funding and/or honoraria from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Gen-entech, Blueprint Medicines, and Novartis and consulting fees and honoraria from Constellation, Pragmatist, Sierra, Incyte, Novartis, and Celgene. The remaining authors declare no competing financial interests. Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology",
year = "2019",
month = may,
day = "23",
doi = "10.1182/blood-2019-01-897637",
language = "English (US)",
volume = "133",
pages = "2348--2351",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",
}